Latest news with #AlecStranahan
Yahoo
24-06-2025
- Business
- Yahoo
BofA Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00. The rating update came after the company announced on May 12 plans to present at the BofA Securities 2025 Healthcare Conference. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. In addition, Sana Biotechnology, Inc. (NASDAQ:SANA) presented positive 4- and 12-week clinical results for its ongoing type 1 diabetes study. The company plans to file Investigational New Drug applications (INDs) for SG299 in B-cell-related diseases and for SC451 in type 1 diabetes as early as 2026. As of fiscal Q1 2025, Sana Biotechnology, Inc. (NASDAQ:SANA) has a cash position of $104.7 million, with an expected cash runway into 2026. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineering cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
BofA Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00. The rating update came after the company announced on May 12 plans to present at the BofA Securities 2025 Healthcare Conference. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. In addition, Sana Biotechnology, Inc. (NASDAQ:SANA) presented positive 4- and 12-week clinical results for its ongoing type 1 diabetes study. The company plans to file Investigational New Drug applications (INDs) for SG299 in B-cell-related diseases and for SC451 in type 1 diabetes as early as 2026. As of fiscal Q1 2025, Sana Biotechnology, Inc. (NASDAQ:SANA) has a cash position of $104.7 million, with an expected cash runway into 2026. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineering cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
14-06-2025
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for RegenXBio (RGNX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $22.00. The company's shares opened today at $9.72. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, RegenXBio, and Candel Therapeutics. According to TipRanks, Stranahan has an average return of -9.6% and a 39.81% success rate on recommended stocks. RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $31.27, a 221.71% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $40.00 price target. Based on RegenXBio's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $89.01 million and a net profit of $6.08 million. In comparison, last year the company earned a revenue of $15.62 million and had a GAAP net loss of $63.33 million
Business Insider
01-06-2025
- Business
- Business Insider
Bank of America Securities Remains a Buy on Revolution Medicines (RVMD)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Revolution Medicines (RVMD – Research Report) on May 30 and set a price target of $78.00. Confident Investing Starts Here: Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Y-Mabs Therapeutics, and TG Therapeutics. According to TipRanks, Stranahan has an average return of -11.2% and a 35.35% success rate on recommended stocks. Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $70.63.
Yahoo
21-05-2025
- Business
- Yahoo
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025. Stranahan cited that this will mitigate near-term risks. However, the analyst pointed out that the post-marketing commitments and the need for further trials are already considered in Novavax's guidance, indicating minimal influence on the stock's performance. A person holding a syringe filled with a vaccine, implying the companys impact on health and wellbeing. As the demand for COVID vaccines remains sizeable among older populations, the stricter labeling may not have a drastic impact on Nuvaxovid's potential market. Overall, the analyst maintains a neutral view on the stock, considering the full potential of Novavax's pipeline remains to be unlocked. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology firm that is engaged in the discovery, development, and commercialization of vaccines to protect against serious diseases worldwide. While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about this cheapest AI stock. Read Next: and . Disclosure. None. Sign in to access your portfolio
